OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AWHL.PK51

Aspira Women's Health Inc

Biotechnology & Medical ResearchVerified

Aspira Women's Health Inc operates with a negative equity position of -$1.363 billion, indicating a significant debt burden relative to its asset base. The company's liquidity position is weak, with a current ratio of 1.16, suggesting limited ability to meet short-term obligations. Despite holding $3.413 billion in cash and equivalents, the company's operating cash flow is negative at -$4.431 billion, reflecting ongoing operational losses. Profitability metrics are concerning, with a return on equity of 3.3962 and a negative return on assets of -0.6461. These figures indicate that the company is not generating returns that exceed its cost of capital and is underperforming relative to industry norms. The debt-to-equity ratio of -1.48 further highlights the company's reliance on debt financing, which increases financial risk. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth opportunities. The absence of segment or geographic breakdown in the financial data suggests a need for more detailed disclosures to assess operational resilience. Looking ahead, the company is projected to maintain a negative revenue trajectory, with no significant growth expected in the current or next fiscal year. The operating losses and negative cash flows indicate a lack of momentum in revenue generation and cost control. The company's capital expenditures are minimal, suggesting a conservative approach to reinvestment. Risk factors include a low liquidity score and a negative equity position, which could constrain the company's ability to fund operations or pursue strategic initiatives. The dilution risk is currently low, but the company's negative equity and high debt levels could necessitate future equity issuances, potentially diluting existing shareholders. Recent filings and transcripts do not indicate any material events that would significantly alter the company's risk profile. The absence of immediate liquidity or dilution flags suggests that the company is not currently facing urgent financial pressures, but the long-term sustainability of its operations remains uncertain.

30-day price · AWHL.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyAspira Women's Health Inc
TickerAWHL.PK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Aspira Women's Health Inc operates with a negative equity position of -$1.363 billion, indicating a significant debt burden relative to its asset base. The company's liquidity position is weak, with a current ratio of 1.16, suggesting limited ability to meet short-term obligations. Despite holding $3.413 billion in cash and equivalents, the company's operating cash flow is negative at -$4.431 billion, reflecting ongoing operational losses. Profitability metrics are concerning, with a return on equity of 3.3962 and a negative return on assets of -0.6461. These figures indicate that the company is not generating returns that exceed its cost of capital and is underperforming relative to industry norms. The debt-to-equity ratio of -1.48 further highlights the company's reliance on debt financing, which increases financial risk. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth opportunities. The absence of segment or geographic breakdown in the financial data suggests a need for more detailed disclosures to assess operational resilience. Looking ahead, the company is projected to maintain a negative revenue trajectory, with no significant growth expected in the current or next fiscal year. The operating losses and negative cash flows indicate a lack of momentum in revenue generation and cost control. The company's capital expenditures are minimal, suggesting a conservative approach to reinvestment. Risk factors include a low liquidity score and a negative equity position, which could constrain the company's ability to fund operations or pursue strategic initiatives. The dilution risk is currently low, but the company's negative equity and high debt levels could necessitate future equity issuances, potentially diluting existing shareholders. Recent filings and transcripts do not indicate any material events that would significantly alter the company's risk profile. The absence of immediate liquidity or dilution flags suggests that the company is not currently facing urgent financial pressures, but the long-term sustainability of its operations remains uncertain.
Key takeaways
  • Aspira Women's Health Inc is operating with a negative equity position and significant debt, indicating high financial leverage and risk.
  • The company's liquidity position is weak, with a current ratio of 1.16 and negative operating cash flow.
  • Profitability metrics are poor, with a negative return on assets and a return on equity that is not indicative of strong performance.
  • The company's revenue is not diversified by segment or geography, increasing exposure to market-specific risks.
  • No immediate liquidity or dilution risks are flagged, but the company's financial position suggests potential for future equity dilution.
  • The outlook for revenue growth is negative, with no significant improvement expected in the near term.
  • --
  • **RATIONALES**:
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$2.2M
Gross profit$1.2M
Operating income-$4.7M
Net income-$4.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.4M
CapEx-$20.0k
Free cash flow-$4.6M
Total assets$7.2M
Total liabilities$8.5M
Total equity-$1.4M
Cash & equivalents$3.4M
Long-term debt$2.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$6.8M-$32.6M-$31.7M-$31.5M
FY-3$8.2M-$31.1M-$29.9M-$29.9M
FY-2$9.2M-$17.9M-$16.7M-$16.5M
FY-1$9.2M-$16.3M-$13.1M-$13.0M
FY0$9.2M-$7.9M-$12.8M-$13.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$41.1M$30.2M$37.2M
FY-3$17.4M$7.0M$13.3M
FY-2$6.3M-$2.4M$2.6M
FY-1$5.5M-$2.6M$1.8M
FY0$5.5M-$6.9M$1.8M
PeriodOCFCapExFCFSBC
FY-4-$27.4M-$184.0k-$31.5M
FY-3-$31.1M-$232.0k-$29.9M
FY-2-$15.9M-$24.0k-$16.5M
FY-1-$12.1M-$37.0k-$13.0M
FY0-$7.0M-$401.0k-$13.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$2.2M-$4.7M-$4.6M-$4.6M
FQ-6$2.4M-$4.4M-$3.5M-$3.5M
FQ-5$2.3M-$3.7M-$3.5M-$3.5M
FQ-4$2.3M-$3.4M-$1.4M-$1.4M
FQ-3$2.3M-$3.2M-$1.9M-$1.8M
FQ-2$2.4M-$1.8M-$2.7M-$2.7M
FQ-1$2.3M-$1.6M-$4.9M-$4.8M
FQ0$2.2M-$1.3M-$3.4M-$3.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$7.2M-$1.4M$3.4M
FQ-6$4.0M-$3.7M$962.0k
FQ-5$4.8M-$2.5M$2.1M
FQ-4$5.5M-$2.6M$1.8M
FQ-3$6.7M-$60.0k$3.3M
FQ-2$4.9M-$2.7M$1.5M
FQ-1$7.3M-$4.3M$3.8M
FQ0$5.5M-$6.9M$1.8M
PeriodOCFCapExFCFSBC
FQ-7-$4.4M-$20.0k-$4.6M
FQ-6-$8.2M-$35.0k-$3.5M
FQ-5-$11.1M-$37.0k-$3.5M
FQ-4-$12.1M-$37.0k-$1.4M
FQ-3-$3.1M$0.00-$1.8M
FQ-2-$4.8M-$2.7M
FQ-1-$5.0M-$393.0k-$4.8M
FQ0-$7.0M-$401.0k-$3.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$1.4M
Net cash$1.4M
Current ratio1.2
Debt/Equity-1.5
ROA-64.6%
ROE3.4%
Cash conversion96.0%
CapEx/Revenue-0.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricAWHL.PKActivity
Op margin-218.8%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-215.0%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin56.4%45.6% medp25 29.8% · p75 66.7%above median
CapEx / revenue-0.9%-5.2% medp25 -15.8% · p75 -1.7%top quartile
Debt / equity-148.0%9.3% medp25 0.1% · p75 43.8%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 02:36 UTC#c8320f95
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 10:42 UTCJob: 585688d3